53 assets in Non-Small Cell Squamous Lung Carcinoma

Therapeutic assets addressing Non-Small Cell Squamous Lung Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Mdna11 Non-Small Cell Squamous Lung Carcinoma	Medicenna Therapeutics, Inc.	P1/2	NR ()
Pevonedistat Non-Small Cell Squamous Lung Carcinoma	National Cancer Institute (NCI)	P2	NR ()
Tak-928 Non-Small Cell Squamous Lung Carcinoma	Takeda	P3	NR ()

Showing 51 to 53 of 53 assets

PreviousPage 2 of 2Next